NovaBay launches Avenova Allograft for corneal repair
NovaBay Pharmaceuticals announced the launch of a prescription optic allograft for protecting the ocular surface, made with BioStem Technologies’ proprietary process.
“Avenova Allograft is a valuable addition to our high-quality, differentiated eye care franchise and allows us to provide another solution for the professionals who specialize in treating eye conditions,” NovaBay CEO and general counsel Justin Hall said in a company press release.
The Avenova Allograft protects the cornea and conjunctiva using only the amnion layer of the placental membrane and is available in 8 mm, 10 mm and 12 mm diameter sizes at 20 to 50 microns thick. BioStem’s patented six-step BioREtain process preserves the natural integrity of the placental tissue.
BioStem Technologies will oversee manufacturing, packaging, shipping and regulatory compliance, while NovaBay will spearhead outreach programs targeted at eye care specialists to educate them on the clinical benefits of the Avenova Allograft as well as the process for Medicare reimbursement.
“We are excited to partner with NovaBay, which shares our commitment to commercializing innovative, best-in-class products that improve people’s quality of life,” BioStem Technologies CEO Jason Matuszewski said in the release. “This relationship allows us to capitalize on NovaBay’s well-established relationships in the eye care sector as we focus on additional market opportunities for tissue allograft products.”
Read more about